"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead
Case report
peer-reviewed

Platinum-Based Chemotherapy Secures Effective Local Control for Very Advanced Hereditary Triple-Negative Breast Cancer with Life-Threatening Bleeding



Abstract

Here we report the case of a noncompliant 50-year-old female patient with high-grade, triple-negative breast cancer (TNBC) and strong family cancer history. She only agreed to start treatment after being admitted to the hospital with advanced stage disease and severe anaemia resulting from bulky, ulcerated, and actively bleeding tumor. Therapy was promptly started with platinum-based chemotherapy, resulting in extremely rapid clinical remission and complete control of local symptoms. In conclusion, we hypothesise that even a single course of platinum-based chemotherapy could bring under control life-threatening complications in hereditary TNBC and, therefore, it should be administered without hesitation in emergency circumstances if the patient can tolerate one dose of the medication.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Case report
peer-reviewed

Platinum-Based Chemotherapy Secures Effective Local Control for Very Advanced Hereditary Triple-Negative Breast Cancer with Life-Threatening Bleeding


Author Information

Arvids Irmejs

Institute of Oncology, Continuing Education, Riga Stradins University, Latvia

Peteris Loza Corresponding Author

Breast Unit, Riga Stradins University Hospital, Riga Stradins University, Latvia

Elina Skuja

Institute of Oncology, Continuing Education, Riga Stradins University, Latvia

Janis Gardovskis

Chief of Surgical Department, Riga Stradins University Hospital, Riga Stradins University, Latvia


Ethics Statement and Conflict of Interest Disclosures

Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: The authors have declared that no conflicts of interest exist.

Acknowledgements

This study was supported by State Research Program "Biomedicine for the public health (BIOMEDICINE)" project 5 "Personalised cancer diagnostics and treatment effectiveness evaluation".


Case report
peer-reviewed

Platinum-Based Chemotherapy Secures Effective Local Control for Very Advanced Hereditary Triple-Negative Breast Cancer with Life-Threatening Bleeding


Figures etc.

Share
Case report
peer-reviewed

Platinum-Based Chemotherapy Secures Effective Local Control for Very Advanced Hereditary Triple-Negative Breast Cancer with Life-Threatening Bleeding

  • Author Information
    Arvids Irmejs

    Institute of Oncology, Continuing Education, Riga Stradins University, Latvia

    Peteris Loza Corresponding Author

    Breast Unit, Riga Stradins University Hospital, Riga Stradins University, Latvia

    Elina Skuja

    Institute of Oncology, Continuing Education, Riga Stradins University, Latvia

    Janis Gardovskis

    Chief of Surgical Department, Riga Stradins University Hospital, Riga Stradins University, Latvia


    Ethics Statement and Conflict of Interest Disclosures

    Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: The authors have declared that no conflicts of interest exist.

    Acknowledgements

    This study was supported by State Research Program "Biomedicine for the public health (BIOMEDICINE)" project 5 "Personalised cancer diagnostics and treatment effectiveness evaluation".


    Article Information

    Published: July 10, 2017

    DOI

    10.7759/cureus.1455

    Cite this article as:

    Irmejs A, Loza P, Skuja E, et al. (July 10, 2017) Platinum-Based Chemotherapy Secures Effective Local Control for Very Advanced Hereditary Triple-Negative Breast Cancer with Life-Threatening Bleeding. Cureus 9(7): e1455. doi:10.7759/cureus.1455

    Publication history

    Received by Cureus: May 25, 2017
    Peer review began: June 14, 2017
    Peer review concluded: July 05, 2017
    Published: July 10, 2017

    Copyright

    © Copyright 2017
    Irmejs et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

    License

    This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Here we report the case of a noncompliant 50-year-old female patient with high-grade, triple-negative breast cancer (TNBC) and strong family cancer history. She only agreed to start treatment after being admitted to the hospital with advanced stage disease and severe anaemia resulting from bulky, ulcerated, and actively bleeding tumor. Therapy was promptly started with platinum-based chemotherapy, resulting in extremely rapid clinical remission and complete control of local symptoms. In conclusion, we hypothesise that even a single course of platinum-based chemotherapy could bring under control life-threatening complications in hereditary TNBC and, therefore, it should be administered without hesitation in emergency circumstances if the patient can tolerate one dose of the medication.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Arvids Irmejs

Institute of Oncology, Continuing Education, Riga Stradins University, Latvia

Peteris Loza

Breast Unit, Riga Stradins University Hospital, Riga Stradins University, Latvia

For correspondence:
peteris.loza@stradini.lv

Elina Skuja

Institute of Oncology, Continuing Education, Riga Stradins University, Latvia

Janis Gardovskis

Chief of Surgical Department, Riga Stradins University Hospital, Riga Stradins University, Latvia

Arvids Irmejs

Institute of Oncology, Continuing Education, Riga Stradins University, Latvia

Peteris Loza

Breast Unit, Riga Stradins University Hospital, Riga Stradins University, Latvia

For correspondence:
peteris.loza@stradini.lv

Elina Skuja

Institute of Oncology, Continuing Education, Riga Stradins University, Latvia

Janis Gardovskis

Chief of Surgical Department, Riga Stradins University Hospital, Riga Stradins University, Latvia